Vivimed Labs' board has approved financial results for the quarter ended June 30, 2025. Consolidated revenue was Rs 21.77 crore.

Auditors qualified results due to Rs 14.98 crore in unrecorded interest expenses, resulting in an adjusted consolidated loss of Rs 20.48 crore (EPS: -Rs 2.47). The company faces Rs 374.82 crore in bank defaults (NPA accounts), though management anticipates a settlement.

Key re-appointments include Mr. Santosh Varalwar as MD, and Mr. Sandeep Varalwar and Mr. Manohar Rao Varalwar as Whole-time Directors for five-year terms.

Pledging overseas entity securities for future funding was also approved.